Lung involvement raises costs for systemic sclerosis patients

Lung involvement raises costs for systemic sclerosis patients PharmacoEconomics & Outcomes News 792, p16 - 2 Dec 2017 Lung involvement raises costs for systemic sclerosis patients Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) substantially increase healthcare costs and have poorer survival outcomes for patients with systemic sclerosis, according to a group of US- based researchers. The retrospective cohort analysis estimated all-cause healthcare use and costs (2014 values) from nationwide claims databases. Data were collected for patients with newly-diagnosed (incident) systemic sclerosis with or without ILD and/or PAH, who were continuously enrolled over a 5-year period. Of patients with continuous enrolment over a 5-year period, 1957 had incident systemic sclerosis, 219 had ILD-related disease and 108 had PAH-related disease. Average all-cause healthcare costs were substantially higher for patients with ILD- ($US191 107) and PAH- related disease ($254 425) over 5 years, compared with patients with non-lung-involved systemic sclerosis ($101 839). A similar pattern was seen for annual costs, where they ranged from $31 285 to $55 446 for the ILD group, $44 454 to $63 320 for the PAH group, and $18 513 to $23 268 for non-lung-involved disease. Median survival time was significantly shorter in the ILD and PAH groups (11.3, 8.8 vs 6.0 years, respectively; p < 0.001). "These data highlight that there remains an unmet need to identify more effective therapeutic strategies for both ILD and PAH", conclude the authors. * Funded by Genentech Inc and F. Hoffmann-La Roche. Fischer A, et al. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. The Journal of Rheumatology : 15 Nov 2017 803284966 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 PharmacoEconomics & Outcomes News Springer Journals

Lung involvement raises costs for systemic sclerosis patients

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial